Lv Q.-Y.,302 Military Hospital |
Li X.-Y.,Institute for Drug and Instrument control |
Shen B.-D.,302 Military Hospital |
Dai L.,302 Military Hospital |
And 4 more authors.
Journal of Nanoparticle Research
The phospholipid-bile salts-mixed micelles (PL-BS-MMs) are potent carriers used for oral absorption of drugs that are poorly soluble in water; however, there are many limitations associated with liquid formulations. In the current study, the feasibility of preparing the fast dissolving oral films (FDOFs) containing PL-BS-MMs was examined. FDOFs incorporated with Cucurbitacin B (Cu B)-loaded PL-sodium deoxycholate (SDC)-MMs have been developed and characterized. To prepare the MMs and to serve as the micellar carrier, a weight ratio of 1:0.8 and total concentration of 54 mg/mL was selected for the PL/SDC based on the size, size distribution, zeta potential, encapsulation efficiency, and morphology. The concentration of Cu B was determined to be 5 mg/mL. Results showed that a narrow size distributed nanomicelles with a mean particle size of 86.21 ± 6.11 nm and a zeta potential of -31.21 ± 1.17 mV was obtained in our optimized Cu B-PL/SDC-MMs formulation. FDOFs were produced by solvent casting method and the formulation with 50 mg/mL of pullulan and 40 mg/mL of PEG 400 were deemed based on the physico-mechanical properties. The FDOFs containing Cu B-PL/SDC-MMs were easily reconstituted in a transparent and clear solution giving back a colloidal system with spherical micelles in the submicron range. In the in vitro dissolution test, the FDOFs containing Cu B-PL/SDC-MMs showed an increased dissolution velocity markedly. The pharmacokinetics study showed that the FDOFs containing PL-SDC-MMs not only kept the absorption properties as same as the PL-SDC-MMs, but also significantly increased the oral bioavailability of Cu B compared to the Cu B suspension (p < 0.05). This study showed that the FDOFs containing Cu B-PL/SDC-MMs could represent a novel platform for the delivery of poorly water-soluble drugs via oral administration. Furthermore, the integration with the FDOFs could also provide a simple and cost-effective manner for the solidification of PL-SDC-MMs. © 2014 Springer Science+Business Media. Source
Li Y.,PLA Fourth Military Medical University |
Yuan J.,PLA Fourth Military Medical University |
Yang Q.,PLA Fourth Military Medical University |
Cao W.,PLA Fourth Military Medical University |
And 5 more authors.
International Journal of Nanomedicine
Liposomes constitute one of the most popular nanocarriers for improving the delivery and efficacy of agents in cancer patients. The purpose of this study was to design and evaluate immunoliposome co-delivery of bufalin and anti-CD40 to induce synergetic therapeutic efficacy while eliminating systemic side effects. Bufalin liposomes (BFL) conjugated with anti-CD40 antibody (anti-CD40-BFL) showed enhanced cytotoxicity compared with bufalin alone. In a mouse B16 melanoma model, intravenous injection of anti-CD40-BFL achieved smaller tumor volume than did treatment with BFL (average: 117 mm3 versus 270 mm3, respectively); the enhanced therapeutic efficacy through a caspase-dependent pathway induced apoptosis, which was confirmed using terminal deoxynucleotidyl transferase-mediated dUTP-Fluorescein nick end labeling and Western blot assay. Meanwhile, anti-CD40-BFL elicited unapparent body-weight changes and a significant reduction in serum levels of tumor necrosis factor-a, interleukin-1p, interleukin-6, interferon-y, and hepatic enzyme alanine transaminase, suggesting minimized systemic side effects. This may be attributed to the mechanism by which liposomes are retained within the tumor site for an extended period of time, which is supported by the following biodistri-bution and flow cytometric analyses. Taken together, the results demonstrated a highly promising strategy for liposomal vehicle transport of anti-CD40 plus bufalin that can be used to enhance antitumor effects via synergetic systemic immunity while blocking systemic toxicity. © 2014 Li et al. Source
Lv Q.,302 Military Hospital |
Li X.,Institute for Drug and Instrument control |
Li R.,Animal Laboratory Center |
Shen B.,302 Military Hospital |
And 5 more authors.
Cucurbitacin B (Cu B), formulated in the phospholipid-bile salts-mixed micelles (PL-BS-MMs), was transformed into dry powders by solidification process. Solidification methods for this transformation included freeze-drying, spray-drying or vacuum-drying, and different grades of process parameters called conservative, moderate and aggressive have been used in each solidification method, respectively. Saccharides (mannose, trehalose and glucose), polyethylene glycol (PEG) and mucoadhesive water-soluble polymers (carrageenan, hydroxpropylmethylcellulose (HPMC) and gelatin) were selected as the stabilizer, respectively. The influence of different stabilizers on the redispersibility of solid Cu B-PL/SDC-MMs was systemically investigated, such as the redispersibility index (RDI). The results showed that there were significant differences in RDI from samples stabilized by different stabilizers. The solid Cu B-PL/SDCMMs stabilized by mucoadhesive water-soluble polymers (carrageenan, HPMC and gelatin) have better redispersibility under different solidification approaches, compared with those samples stabilized by other stabilizers. The results indicated that the mucoadhesive water-soluble polymers could effectively counter various stresses from the solidification process and prevent the nanocrystal surface from agglomeration. The combined action between steric hindrance and increased viscosity appeared to effectively avoid irreversible particle aggregation. Source
Li Y.,PLA Fourth Military Medical University |
Zhao H.,PLA Fourth Military Medical University |
Duan L.-R.,PLA Fourth Military Medical University |
Li H.,PLA Fourth Military Medical University |
And 4 more authors.
Colloids and Surfaces A: Physicochemical and Engineering Aspects
The aim of this study was to investigate the potential effect of pectin for liposomal drug delivery systems. An orthogonal L9 (33) test was designed to optimize the preparation condition of cationic bufalin liposomes coated with commercially available citrus pectin (CPL). The change in particle size, zeta potential, entrapment efficiency, stability, mucoadhesion and anticancer effect were evaluated. The results showed that CPL had an excellent stability and mucoadhesive properties, and the drug release in vitro was modest prolonged and sustained. Furthermore, the inhibition effect of liposomes on SW480 colon cancer cells was dramatic enhanced due to a block of cell cycle at G0/G1 phase, and CPL had a higher inhibition rate than bufalin liposomes (BFL) because of the anticancer effect of citrus pectin. It is concluded that CPL is a potentially promising drug carrier system treatment for colon cancer. © 2013 Elsevier B.V. Source
Kong X.,University of Sichuan |
Kong A.,Institute for Drug and Instrument control
Current Drug Metabolism
Tea is an infusion of the leaves of the Camellia sinensis plant and is the most widely consumed beverage in the world after water. The main chemical components in teas are phenolic compounds (tea polyphenols, mainly tea catechins). A large number of in vitro and in vivo scientific studies have supported that the tea polyphenols can provide a number of health benefits such as, reducing the incidence of coronary heart disease, diabetes and cancer. Recently, tea polyphenols have proven highly attractive as lead compounds for drug discovery programs. A clear understanding of chemistry, stability, pharmacokinetics and metabolic fate of tea will be significant to elucidate many medicinal effects by biochemical theory and pharmaceutical development. This article reviews the current literature on the pharmacoknetics and biotransformation of tea catechins. The half-lives of tea polyphenols are 2-4h and their absorption and elimination are rapid in humans. The peak times (tmax) are 1 and 3 h after oral administration and the peak plasma concentrations are low μM range. It has been reported that catechins are easily metabolized by enzyme and microbe, and the main metabolic pathways are methylation, glucuronidation, sulfation, ring-fission metabolism, and so on. The information is important to discuss some of the challenges and benefits of pursuing this family of compounds for drug discovery. © 2014 Bentham Science Publishers. Source